As an upstream regulator of EGFR, LAMC2 not only predicts high gefitinib sensitivity, but may also serve as a potential biomarker for predicting EGFR TKI response as well as for identifying and stratifying LAMC2high-EGFRhigh NSCLC patients for EGFR TKI treatment. Here, LAMC2 is linked to non-small cell lung carcinoma.